The treatment landscape for melanoma saw significant advancements in 2024, as highlighted by Elisa Funck-Brentano, MD, PhD, from Ambroise-Paré Hospital in Paris, France, during her presentation at the 2024 Dermatology Days of Paris conference in Paris.
Checkpoint Inhibitors in Neoadjuvant Therapy
The standard approach for treating resectable stage III melanoma with locoregional metastases has traditionally involved surgery followed by adjuvant therapy. However, the phase 3 NADINA trial, published in 2024, is driving a paradigm shift. The trial demonstrated that bi-immunotherapy with ipilimumab and nivolumab administered before surgery, followed by tailored adjuvant therapy based on pathologic response, significantly outperformed nivolumab monotherapy in both event-free survival and metastasis-free…